SOST and chronic kidney disease: A range of studies suggest an initial increase of sclerostin synthesis by the osteocyte during the course of CKD, but the subsequent increase of PTH inhibits SOST and sclerostin expression [54, 56] and in fact, sclerostin correlates negatively with PTH and bone turnover markers.